US20030012775A1 - PEG conjugates of NK4 - Google Patents

PEG conjugates of NK4 Download PDF

Info

Publication number
US20030012775A1
US20030012775A1 US10/081,309 US8130902A US2003012775A1 US 20030012775 A1 US20030012775 A1 US 20030012775A1 US 8130902 A US8130902 A US 8130902A US 2003012775 A1 US2003012775 A1 US 2003012775A1
Authority
US
United States
Prior art keywords
peg
monopegylated
kda
group
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/081,309
Other languages
English (en)
Inventor
Michael Brandt
Apollon Papadimitriou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoffmann La Roche Inc
Original Assignee
Hoffmann La Roche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche Inc filed Critical Hoffmann La Roche Inc
Assigned to F. HOFFMANN-LA ROCHE AG reassignment F. HOFFMANN-LA ROCHE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRANDT, MICHAEL, PAPADIMITRIOU, APOLLON
Assigned to HOFFMANN-LA ROCHE INC. reassignment HOFFMANN-LA ROCHE INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: F.HOFFMANN-LA ROCHE AG
Assigned to HOFFMANN-LA ROCHE INC. reassignment HOFFMANN-LA ROCHE INC. DOCUMENT PREVIOUSLY RECORDED AT REEL 012910 FRAME 0411 CONTAINED AN ERROR IN PROPERTY NUMBER 10081301. DOCUMENT RE-RECORDED TO CORRECT ERRORS ON STATED REEL. ASSIGNORS HEREBY CONFIRMS THE ASSIGNMENT OF THE ENTIRE INTEREST. Assignors: F. HOFFMANN-LA ROCHE AG
Publication of US20030012775A1 publication Critical patent/US20030012775A1/en
Priority to US11/869,797 priority Critical patent/US7846896B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Hepatocyte growth factor is a polypeptide identified and purified by Nakamura, T., et al., Biochem. Biophys. Res. Commun. 22 (1984) 1450-1459. It was further found that hepatocyte growth factor is identical to scatter factor (SF), Weidner, K. M., et al., Proc. Natl. Acad. Sci. USA 88 (1991) 7001-7005.
  • HGF is a glycoprotein with a molecular weight of about 100 kDa involved in the development of a number of cellular phenotypes including proliferation, mitogenesis, formation of branching tubules and, in the case of tumor cells, invasion and metastasis.
  • U.S. Pat. No. 5,977,310 describes PEG-modified HGF.
  • PEG-modified HGF has a prolonged clearance in vivo and has the same physiological activity as HGF.
  • the molar amount of the PEG reagent may be selected from the range of from 5 to 100 times of the molar weight of HGF.
  • a preferred molar range of the PEG reagent is of from 10 to 25 times of the molar weight of HGF.
  • the molecular weight of the attached PEG chain was about 10 kDa.
  • the molecules may aquire a prolonged half-life in vivo and, in the case of heterologous proteins, reduced immunogenicity, but at the expense of a significant or complete loss of the desired biological activities (see, e.g., Kitamura, K., et al., Cancer Res. 51 (1991) 4310-4315 and Maiti, P. K., et al., Int. J. Cancer Suppl. 3 (1988) 17-22).
  • PEGylated IFN- ⁇ shows, for example, only 7% of the potency compared to non-PEGylated IFN- ⁇ (Bailon, P., Bioconjugate Chem. 12 (2001) 195-202).
  • HGF/SF fragment termed NK4, consisting of the N-terminal hairpin domain and the four kringle domains of HGF/SF, has pharmacological properties that are completely different from those of HGF/SF, and is an antagonist to the influence of HGF/SF on the motility and the invasion of colon cancer cells, and is, in addition, an angiogenesis inhibitor that suppresses tumor growth and metastasis (WO 93/23541; Parr, C., et al., Int. J. Cancer 85 (2000) 563-570; Kuba, K., et al., Cancer Res.
  • NK4 had to be infused continuously over a period of two weeks.
  • Francis, G. E., et al., Int. J. Hematol. 68 (1998) 1-18 present an overview of PEGylation of cytokines and other therapeutic proteins.
  • Francis et al. state that with the majority of methods of PEGylation, substantial reduction of bioactivity has been reported (typically, 20-95%).
  • PEGylation of proteins is always based on trial and error and virtually all parameters of such a PEGylation can have a surprising and very profound effect on the functionality of the product.
  • Tsutsumi, Y., et al., Thromb. Haemost. 77 (1997) 168-173 describes the PEGylation of Interleukin-6.
  • Tsutsumi et al. about 54% of the lysine amino groups of IL-6 were coupled with PEG with a molecular weight of 5 kDa per PEG group.
  • Tsutsumi et al. in Proc. Natl. Acad. Sci. USA 97 (2000) 8548-8553, describe the chemical modification of an immunotoxin by PEG. As random PEGylation was accompanied by a significant loss of specific cytotoxic activity, Tsutsumi performs a site-specific PEGylation by using an immunotoxin mutant with one or two additional cysteins which are used for PEG coupling. Heinzerling, L., et al., Dermatol.
  • the present invention provides a conjugate consisting of a NK4 molecule and a polyethylene glycol group having a molecular weight of from about 20 to about 40 kDa.
  • the present invention provides a composition comprising conjugates of NK4 monoPEGylated with polyethylene glycol groups that have a molecular weight of from about 20 to about 40 kDa, wherein the conjugates comprise conjugates in which the polyethylene glycol groups are randomly attached to groups of the NK4 molecules selected from the lysine side chains of NK4 molecules and the N-terminal amino groups of NK4 molecules.
  • the present invention also provides a composition comprising conjugates of NK4 monoPEGylated with polyethylene glycol groups that have a molecular weight of from about 20 to about 40 kDa, wherein the monoPEGylated conjugates comprise at least 90% of the total of pegylated NK4 molecules and unpegylated NK4 molecules in the composition.
  • the present invention further provides a method for the treatment of cancer wherein 1 to 30 mg of the monoPEGylated NK4 is administered per kg per day to a patient in need of treatment.
  • SEQ ID NO:1 shows the DNA and polypeptide sequence of NK4.
  • SEQ ID NO:2 shows the polypeptide sequence of NK4.
  • FIG. 1 Inhibition of HGF-induced HUVEC proliferation by NK4, 20 kDa-mono-PEG-NK4 and 30 kDa-mono-PEG-NK4.
  • FIG. 2 Inhibition of HGF-induced HUVEC proliferation by NK4 and 40 kDa-mono-PEG-NK4.
  • FIG. 3 Inhibition of bFGF-induced HUVEC proliferation by NK4, 30 kDa-mono-PEG-NK4 and 40 kDa-mono-PEG-NK4.
  • FIG. 4A Time-concentration curve of NK4, 30 kDa-monoPEG-NK4, 40 kDa-mono-PEG-NK4 in plasma after i.v. administration.
  • FIG. 4B Time-concentration curve of NK4, 30 kDa-monoPEG-NK4, 40 kDa-mono-PEG-NK4 in plasma after s.c. injection.
  • the present invention provides NK4 conjugates consisting of NK4 being covalently linked to one polyethylene glycol (PEG) group of from about 20 to about 40 kDa (monoPEGylated NK4), preferably via an ⁇ -amino group of NK4 lysine or the N-terminal amino group.
  • PEG polyethylene glycol
  • NK4 is randomly PEGylated at one amino group out of the group consisting of the ⁇ -amino groups of NK4 lysine and the N-terminal amino group.
  • Human HGF is a disulfide-linked heterodimer, which can be cleaved in an ⁇ -subunit of 463 amino acids and a ⁇ -subunit of 234 amino acids, by cleavage between amino acids R494 and V495.
  • the N-terminus of the ⁇ -chain is preceded by 31 amino acids started with a methionine group. This segment includes a signal sequence of 31 amino acids.
  • the ⁇ -chain starts at amino acid 32 and contains four kringle domains.
  • the so-called “hairpin domain” consists of amino acids 70-96.
  • the kringle 1 domain consists of amino acids 128-206.
  • the kringle 2 domain consists of amino acids 211-288
  • the kringle 3 domain consists of amino acids 305-383
  • the kringle 4 domain consists of amino acids 391-469 of the ⁇ -chain, approximately.
  • NK4 essentially not affecting the biological properties of NK4 (especially not affecting its activities antagonistic to HGF and its antiangiogenic activities), which variations are described, for example, in WO 93/23541.
  • the length of NK4 can vary within a few amino acids as long as its biological properties are not affected.
  • NK4 is composed of the N-terminal 447 amino acids of the HGF/SF ⁇ -chain, which includes the above-mentioned hairpin domain and the four kringle domains. It can be produced recombinantly, either by the production of recombinant human HGF/SF and digestion with elastase (Date, K., FEBS Letters 420 (1997) 1-6) or by recombinant expression of an NK4 encoding nucleic acid in appropriate host cells, as described below. NK4 glycoprotein has a molecular weight of about 57 kDa (52 kDa for the polypeptide part alone) and has the in vivo biological activity of causing inhibition of tumor growth, angiogenesis and/or metastasis.
  • “MonoPEGylated NK4” as used herein means that NK4 has attached covalently one polyethylene glycol group with a molecular weight of from about 20 to about 40 kDa.
  • the group can be attached, preferably randomly, at one of various sites of the NK4 molecule, preferably, however, at one of the most reactive sites, e.g., of the lysine side chains and the N-terminal amino group.
  • MonoPEGylated NK4 (which therefore preferably is a mixture of monoPEGylated NK4 molecules, PEGylated at different sites which are the ⁇ -amino groups of NK4 lysine and the N-terminal amino group) is at least 90% of the preparation, and most preferably, the monoPEGylated NK4 is 92%, or more, of the preparation of the present invention.
  • the monoPEGylated NK4 preparations according to the invention are homogeneous enough to display the advantages of a substantially homogeneous preparation, e.g., in a pharmaceutical application. “Substantially homogeneous” as used herein means that the only PEG-NK4 conjugate molecules produced, contained or used are those having one PEG group attached.
  • the monoPEGylated NK4 preparation of the present invention may contain unreacted (i.e., lacking PEG group) protein and/or multiPEGylated NK4.
  • unreacted protein i.e., lacking PEG group
  • multiPEGylated NK4 i.e., lacking PEG group
  • peptide mapping and N-terminal sequencing one example below provides a preparation which is at least 90% monoPEG-NK4 conjugate and at most 2% unreacted protein.
  • the PEG polymer molecules used according to the invention have a molecular weight of from about 20 to about 40 kDa, whereby PEG polymers with about 20, 30 or 40 kDa are preferred (by “molecular weight” as used here there is to be understood the mean molecular weight of the PEG; the term “about” indicates that in said PEG preparations, some molecules will weigh more and some less than the stated molecular weight).
  • PEG or PEG group means a residue containing poly(ethylene glycol) as an essential part.
  • a PEG can contain further chemical groups which are necessary for binding reactions; which results from the chemical synthesis of the molecule; or which is a spacer for optimal distance of parts of the molecule.
  • PEG can consist of one or more PEG side-chains which are linked together. PEGs with more than one PEG chain are called multiarmed or branched PEGs. Branched PEGs can be prepared, for example, by the addition of polyethylene oxide to various polyols, including glycerol, pentaerythriol, and sorbitol.
  • a four-armed branched PEG can be prepared from pentaerythriol and ethylene oxide.
  • Branched PEG are described in, for example, EP-A 0 473 084 and U.S. Pat. No. 5,932,462.
  • PEGs with two PEG side-chains (PEG2) linked via the primary amino groups of a lysine (Monfardini, C., et al., Bioconjugate Chem. 6 (1995) 62-69).
  • PEG polymers with a molecular weight of 20-30 kDa linear PEG molecules are preferred and as PEG polymers with a molecular weight of more than 30 kDa, especially with 40 kDa, branched PEGs are preferred.
  • PEG 40 kDa a two-armed PEG (PEG2) is particularly preferred.
  • a method for the production of a monoPEGylated NK4 preparation is provided.
  • PEGylation of NK4 can be performed according to the methods of the state of the art, for example by reaction of NK4 with electrophilically actived PEGs (supplier: Shearwater Corp., USA, www.shearwatercorp.com).
  • Preferred PEG reagents are, e.g., N-hydroxysuccinimidyl propionates (PEG-SPA) or butanoates (PEG-SBA) or branched N-hydroxysuccinimides such as mPEG2-NHS (Monfardini, C., et al., Bioconjugate Chem. 6 (1995) 62-69).
  • NK4 polypeptide which is randomly PEGylated at an ⁇ -amino group of an NK4 lysine or the N-terminal amino group.
  • N-terminally PEGylated NK4 can be produced according to WO 94/01451.
  • said NK4 is covalently linked to one poly(ethylene glycol) group of the formula
  • P is the group of an NK4 protein as described herein, (i.e. without the amino group or amino groups which form an amide linkage with the carbonyl shown in formula (I); and wherein R is lower alkyl; x is 2 or 3; m is from about 450 to about 950 and is chosen so that the molecular weight of the conjugate minus the NK4 protein is from about 20 to about 40 kDa.
  • R is lower alkyl
  • x is 2 or 3
  • m is from about 450 to about 950 and is chosen so that the molecular weight of the conjugate minus the NK4 protein is from about 20 to about 40 kDa.
  • the given ranges of “m” have an orientational meaning. The ranges of “m” are determined in any case, and exactly, by the molecular weight of the PEG group.
  • said NK4 is covalently linked to one poly(ethylene glycol) group of the formula
  • y is 1 to 4, preferably 4, n and p together are chosen such that the molecular weight of the conjugate minus the NK4 protein is from about 20 to 40 kDa, preferably 40 kDa, and n and p differ by not more than 25%, preferably by not more than 10%, and most preferably are identical, and R is lower alkyl.
  • lower alkyl means a linear or branched alkyl group having from one to six carbon atoms (C 1 -C 6 ) alkyl). Examples of lower alkyl groups include methyl, ethyl and isopropyl. In accordance with this invention, R is any lower alkyl. Conjugates in which R is methyl are preferred.
  • m represents the number of ethylene oxide groups (OCH 2 CH 2 ) in the poly(ethylene oxide) group.
  • a single PEG subunit of ethylene oxide has a molecular weight of about 44 daltons.
  • the molecular weight of the conjugate depends on the number “m”.
  • “m” is from about 450 to about 950 (corresponding to a molecular weight of about 20 kDa to about 40 kDa).
  • the number m is selected such that the resulting conjugate of this invention has a physiological activity comparable to unmodified NK4, which activity may represent the same as, more than, or a fraction of the corresponding activity of unmodified NK4.
  • a molecular weight of “about” a certain number means that it is within a reasonable range of that number as determined by conventional analytical techniques.
  • the number “m” is selected so that the molecular weight of each poly(ethylene glycol) group that is covalently linked to the NK4 protein is from about 20 kDa to about 40 kDa.
  • the compound of formula (I) can be prepared, for example, from a known activated polymeric material:
  • succinimidyl ester is a leaving group causing the amide formation.
  • succinimidyl esters such as the compounds of formula II to produce conjugates with proteins are disclosed in U.S. Pat. No. 5,672,662, issued Sep. 30, 1997 (Harris, et al.).
  • Human NK4 contains 30 free ⁇ -amino groups of 30 lysine residues.
  • PEGylation reagent was combined with a SBA compound of Formula II, it has been found that at a protein concentration of about 5 to 10 mg/ml, at a pH of about 7.0 to 8.0, a protein:PEG ratio of about 1:3 and a reaction temperature of from 20-25° C., a mixture of mono-, di-, and trace amounts of the tri-PEGylated species were produced.
  • the protein:PEG ratio was about 1:1 or 1:2 (for example, preferably about 1:2 for 30 kDa PEG-SBA and about 1:5 for 40 kDa PEG2-NHS), primarily the monoPEGylated species is produced.
  • the relative amounts of the different monoPEGylated species can be optimized.
  • Typical, but not limiting, conditions are about 8 to 12 mg/ml NK4, 0.3 M potassium phosphate, pH 8, 25° C., reaction time of 1 h.
  • the yield is about 38% monoPEGylated NK4.
  • Monopegylated NK4 can also be produced according to the methods described in WO 94/01451.
  • WO 94/01451 describes a method for preparing a recombinant polypeptide with a modified terminal amino acid alpha-carbon reactive group. The steps of the method involve forming the recombinant polypeptide and protecting it with one or more biologically added protecting groups at the N-terminal alpha-amine and C-terminal alpha-carboxyl. The polypeptide can then be reacted with chemical protecting agents to selectively protect reactive side chain groups and thereby prevent side chain groups from being modified.
  • the polypeptide is then cleaved with a cleavage reagent specific for the biological protecting group to form an unprotected terminal amino acid alpha-carbon reactive group.
  • the unprotected terminal amino acid alpha-carbon reactive group is modified with a chemical modifying agent.
  • the side chain protected terminally modified single copy polypeptide is then deprotected at the side chain groups to form a terminally modified recombinant single copy polypeptide.
  • the number and sequence of steps in the method can be varied to achieve selective modification at the N- and/or C-terminal amino acid of the polypeptide.
  • NK4 protein being covalently linked to a lower-alkoxy poly(ethylene glycol) group via a linker of the formula
  • X is —(CH 2 ) k — or —CH 2 (O—CH 2 —CH 2 ) k —, k is from 1 to 10, Y is
  • the average molecular weight of the poly(ethylene glycol) moiety is from about 20 kDa to about 40 kDa and the molecular weight of the conjugate is from about 72 kDa to about 92 kDa at a molecular weight of 52 kDa for NK4 polypeptide, or from about 77 kDa to about 97 kDa at a molecular weight of 57 kDa for NK4 glycoprotein.
  • This NK4 species may also be represented by formula (III)
  • R may be any lower alkyl, by which is meant a linear or branched alkyl group having from one to six carbon atoms such as methyl, ethyl, isopropyl, etc.
  • a preferred alkyl is methyl.
  • X may be —(CH 2 ) k — or —CH 2 (O—CH 2 —CH 2 ) k —, wherein k is from 1 to about 10.
  • k is from 1 to about 4, more preferably, k is 1 or 2.
  • X is —(CH 2 ).
  • the number m is selected such that the resulting conjugate of formula (III) has a physiological activity comparable to unmodified NK4, which activity may represent the same as, more than, or a fraction of the corresponding activity of unmodified NK4.
  • m represents the number of ethylene oxide chains in the PEG unit.
  • a single PEG subunit of —(OCH 2 CH 2 )— has a molecular weight of about 44 daltons.
  • the molecular weight of the conjugate depends on the number m.
  • a molecular weight of “about” a certain number means that it is within a reasonable range of that number as determined by conventional analytical techniques.
  • m is therefore an integer ranging from about 450 to about 950 (corresponding to a molecular weight of from about 20 to about 40 kDA).
  • NK4 proteins of formula (III) are represented by the formulae:
  • NK4 protein products are represented by the formula:
  • NK4 proteins may be prepared by
  • P is an NK4 protein less the amino group which forms an amide linkage
  • Z is a reactive group, e.g. a carboxylic-NHS ester
  • X is —(CH 2 )k— or —CH 2 (O—CH 2 —CH 2 ) k —, wherein k is from 1 to about 10
  • Q is a protecting group, like alkanoyl, e.g. acetyl.
  • step (b) covalently reacting the intermediate with an amide linkage from step (a) with an activated polyethylene glycol derivative represented by the formula, W—[OCH 2 CH 2 ] m —OR, to form an NK4 protein product represented by the formula:
  • W is a sulfhydryl reactive form of Y
  • m is an integer ranging from about 450 to about 950
  • R is lower alkyl
  • Y is as defined above.
  • the bi-functional reagent is preferably N-succinimidyl-S-acetylthiopropionate or N-succinimidyl-S-acetylthioacetate
  • Z is preferably N-hydroxy-succinimide
  • the activated polyethylene glycol derivative W—[OCH 2 CH 2 ] m —OR is preferably selected from the group consisting of iodo-acetyl-methoxy-PEG, methoxy-PEG-vinylsulfone, and methoxy-PEG-maleimide.
  • the NK4 proteins of formula (III) may be prepared by covalent linking of a thiol group to NK4 (“activation”) and coupling the resulting activated NK4 with a poly(ethylene glycol) (PEG) derivative.
  • the first step for the preparation of monoPEGylated NK4 according to the present invention comprises covalent linking of a thiol group via NH 2 -groups of NK4.
  • NK4 This activation of NK4 is performed with bi-functional reagents which carry a protected thiol group and an additional reactive group, such as active esters (e.g., a succinimidylester), anhydrides, esters of sulphonic acids, halogenides of carboxylic acids and sulphonic acids, respectively.
  • active esters e.g., a succinimidylester
  • esters of sulphonic acids e.g., a succinimidylester
  • esters of sulphonic acids esters of sulphonic acids
  • halogenides of carboxylic acids and sulphonic acids respectively.
  • the thiol group is protected by groups known in the art, e.g., acetyl groups.
  • These bi-functional reagents are able to react with the amino groups by forming an amide linkage.
  • the activation of the amino groups is performed by reaction with bi-functional reagents having a succinimidyl moiety.
  • the bi-functional reagents may carry different spacer species, e.g. —(CH 2 ) k — or —CH 2 —(O—CH 2 —CH 2 —) k — moieties, wherein k is from 1 to about 10, preferably from 1 to about 4, and more preferably 1 or 2, and most preferably 1.
  • these reagents are N-succinimidyl-S-acetylthiopropionate (SATP) and N-succinimidyl-S-acetylthioacetate (SATA)
  • NK4 thiol group
  • reaction parameters i.e., the protein (NK4) concentration and the protein/bi-functional reagent ratio.
  • the reaction is carried out, for example, in an aqueous buffer solution, pH 6.5-8.0, e.g., in 10 or 100 mM potassium phosphate, with or without 300 mM NaCl, pH 7.3.
  • the bi-functional reagent may be added in DMSO. After completion of the reaction, preferably after 30 minutes, the reaction is stopped by addition of lysine. Excess bifunctional reagent may be separated by methods known in the art, e.g., by dialysis or column filtration.
  • the average number of thiol groups added to NK4 can be determined by photometric methods described in, for example, Grasetti, D. R., and Murray, J. F. in J. Appl. Biochem. Biotechnol. 119 (1967) 41-49.
  • PEG polyethylene glycol
  • Activated PEG derivatives are known in the art and are described in, for example, Morpurgo, M., et al. J. Bioconj. Chem. 7 (1996) 363 ff for PEG-vinylsulfone. Linear chain and branched chain PEG species are suitable for the preparation of the compounds of Formula 1. Examples of reactive PEG reagents are iodo-acetyl-methoxy-PEG and methoxy-PEG-vinylsulfone:
  • the PEG species are activated by maleimide using (alkoxy-PEG-maleimide), such as methoxy-PEG-maleimide (MW 20,000 to 40,000; Shearwater Polymers, Inc.).
  • alkoxy-PEG-maleimide such as methoxy-PEG-maleimide (MW 20,000 to 40,000; Shearwater Polymers, Inc.).
  • the structure of alkoxy-PEG-maleimide is as follows:
  • R and m are as defined above, preferably
  • the coupling reaction with alkoxy-PEG-maleimide takes place after in situ cleavage of the thiol protecting group in an aqueous buffer solution, e.g. 10 mM potassium phosphate, 300 mM NaCl, 2 mM EDTA, pH 6.2.
  • the cleavage of the protecting group may be performed, for example, with hydroxylamine in DMSO at 25° C., pH 6.2 for about 90 minutes.
  • the molar ratio of activated NK4/alkoxy-PEG-maleimide should be from about 1:1 to about 1:6.
  • the reaction may be stopped by addition of cysteine and reaction of the remaining thiol (—SH) groups with N-methylmaleimide or other appropriate compounds capable of forming disulfide bonds. Because of the reaction of any remaining active thiol groups with a protecting group such as N-methylmaleimide or other suitable protecting group, the NK4 proteins in the conjugates of this invention may contain such protecting groups. Generally the procedure described herein will produce a mixture of molecules having varying numbers of thiols protected by different numbers of the protecting group, depending on the number of activated thiol groups on the protein that were not conjugated to PEG-maleimide.
  • N-methylmaleimide forms the same type of covalent bond when used to block the remaining thiol-groups on the PEGylated protein
  • disulfide compounds will lead in an intermolecular sulfide/disulfide exchange reaction to a disulfide bridged coupling of the blocking reagent.
  • Preferred blocking reagents for that type of blocking reaction are oxidized glutathione (GSSG), cysteine and cystamine. Whereas with cysteine no additional net charge is introduced into the PEGylated protein, the use of the blocking reagents GSSG or cystamine results in an additional negative or positive charge.
  • the further purification of the compounds of formula (III), including the separation of mono- from di-, tri- and multi-PEGylated NK4 species, may be done by methods known in the art, e.g., column chromatography.
  • the percentage of mono-PEG conjugates can be controlled by pooling broader fractions around the elution peak to increase the percentage of mono-PEG in the composition.
  • About ninety percent mono-PEG conjugates is a good balance of yield and activity.
  • Compositions in which, for example, at least ninety-two percent or at least ninety-six percent of the conjugates are mono-PEG species may be desired.
  • the percentage of mono-PEG conjugates is from ninety percent to ninety-six percent.
  • the compounds of the present invention can be formulated according to methods for the preparation of pharmaceutical compositions which methods are known to the person skilled in the art.
  • monoPEGylated NK4 according to the invention is combined in a mixture with a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier are described, for example, in Remington's Pharmaceutical Sciences, 18 th edition, 1990, Mack Publishing Company, edited by Oslo et al. (e.g. pp. 1435-1712).
  • Typical compositions contain an effective amount of the substance according to the invention, for example from about 0.1 to 100 mg/ml, together with a suitable amount of a carrier.
  • the compositions may be administered parenterally.
  • This invention further provides pharmaceutical compositions comprising monoPEGylated NK4, in which the percentage of mono-PEG conjugates is preferably at least ninety percent, more preferably at least ninety-two percent.
  • compositions according to the invention can be prepared according to known methods in the art. Usually, solutions of monoPEGylated NK4 are dialyzed against the buffer intended to be used in the pharmaceutical composition and the desired final protein concentration is adjusted by concentration or dilution.
  • Such pharmaceutical compositions may be used for administration for injection and contain an effective amount of the monoPEGylated NK4 together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers.
  • Such compositions include diluents of various buffer contents (e.g. arginine, acetate, phosphate), pH and ionic strength, additives such as detergents and solubilizing agents (e.g. Tween 80/polysorbate, pluronic F68, sodium chloride, sodium sulfate), antioxidants (e.g.
  • compositions may influence the physical state stability rate of release and clearance of the monoPEGylated NK4 according to the invention.
  • the present invention provides for improved NK4 activity and a pharmaceutical composition which can be administered in only a few bolus applications per week and/or in very low dosages, and which are capable of suppressing tumor growth, angiogenesis and metastasis.
  • the amount of PEGylated NK4 used in pharmaceutical treatment is about 50% or lower, preferably about 20% or lower, and most preferably about 10% or lower than the required amount of unPEGylated NK4.
  • the invention provides methods for the treatment of human cancer (e.g. breast, lung, prostate, pancreas or colon cancer) characterized in that a pharmaceutically effective amount of monoPEGylated NK4 is administered in one to seven bolus applications per week to the patient in need thereof.
  • human cancer e.g. breast, lung, prostate, pancreas or colon cancer
  • patients are treated with dosages in the range between from 1 to 30 mg of monoPEGylated NK4 per kg per day over a certain period of time, lasting from one day to about 30 days or even longer.
  • Drug is applied as a single daily subcutaneous or i.v. bolus injection of a pharmaceutical formulation containing 0.1 to 100 mg monoPEGylated NK4 per ml.
  • This treatment can be combined with any standard (e.g. chemotherapeutic) treatment, by applying monoPEGylated NK4 before, during or after the standard treatment. This results in an improved outcome compared to standard treatment alone.
  • the overall amount of administered PEGylated NK4 according to the invention is considerably lower than the amount of NK4 for the same treatment.
  • NK4 for therapeutic uses may be produced by recombinant means using bacterial or eukaryotic expression systems.
  • Suitable eukaryotic expression systems are for example engineered HeLa, BHK or preferably CHO cells.
  • Cells engineered for NK4 production are cultivated in a suitable medium.
  • a 1 to 5 liter cell culture is used as inoculum for a 10 liter fermenter.
  • the culture in the 10 liter fermenter can be used as inoculum for the 100 liter fermenter.
  • this culture can be used as inoculum for the 1000 liter production fermenter.
  • cells are removed by filtration or centrifugation and discarded.
  • the NK4 containing supernatant is filtered, collected and processed during purification. The purification process is described in the following example.
  • Heparin-Sepharose consists of Separose beads to the surface of which heparin is covalently bound. Since NK4 shows a high affinity to heparin it is retained on this column and can be eluted with high salt concentrations, whereas protein contaminants and other impurities either do not bind or elute at lower salt concentrations. NK4 containing fractions, eluting at about 0.7 to 1.1 M NaCl in 50 mM Hepes pH 7.5 are collected and loaded onto a hydroxyapatite column. NK4 elutes with about 0.4 to 0.7 M potassium phosphate, pH 7.5. The resulting fractions are substantially free of contaminating proteins and can be further purified by S-sepharose chromatography.
  • NK4 purified in accordance with the above mentioned procedure was used for PEGylation reactions. Three suitable methods are described.
  • the reaction was stopped by the addition of 10 mM Tris-buffer or arginine HCl, pH 8, and samples were analyzed by SDS-PAGE or size exclusion chromatography on a Superose 6 column (Pharmacia) using as buffer solution 500 mmol/l potassium phosphate, pH 6.8, for equilibration and elution.
  • the reaction was optimized by varying protein to reagent ratio, pH, time and temperature, in order to obtain predominantly monoPEGylated NK4.
  • Such conditions are, for example:
  • Buffer system/pH 0.3 M potassium phosphate, pH 8.
  • NK4 protein concentration 8 to 12 mg/ml in 0.3 M potassium phosphate, pH 8
  • methoxy-PEG-SPA 5 kDa for comparison and 20 kDa, respectively; Shearwater Polymers, Inc., Huntsville Ala.
  • Reaction was carried out at a protein to reagent ratio of 1:2 for about 2 h at room temperature.
  • the reaction was stopped by the addition of 10 mM Tris-buffer or arginine HCl and samples were analyzed by SDS-PAGE, reversed phase HPLC or size exclusion chromatography on a Superose 6 column (Pharmacia) using as buffer solution 500 mmol/l potassium phosphate, pH 6.8, for equilibration and elution.
  • the reaction was optimized by varying protein to reagent ratio, pH, time and temperature, in order to obtain predominantly monoPEGylated NK4, compared to di-and tri-PEGylated NK4.
  • MonoPEGylated NK4 can be separated from unPEGylated, di- and tri-PEGylated NK4 by running a preparative size exclusion chromatography (e.g. Superose 6 or Superdex 200; Pharmacia) using as buffer solution 500 mmol/l K-phosphate pH 6.8, for equilibration and elution, or by ion exchange chromatography.
  • the purified protein contains predominantly the monoPEGylated species. Fractions were collected and analyzed by SDS-PAGE and reversed phase chromatography.
  • the monoPEGylated species elutes earlier in size exclusion chromatography (e.g. Superose 6 or Superdex 200; Pharmacia; using as buffer solution 500 mmol/l K-phosphate pH 6.8, for equilibration and elution) as compared to the unmodified form. This is due to an increased hydrodynamic radius of the molecule.
  • size exclusion chromatography e.g. Superose 6 or Superdex 200; Pharmacia; using as buffer solution 500 mmol/l K-phosphate pH 6.8, for equilibration and elution
  • NK4 Digestion of monoPEGylated NK4 with sequence-specific endo-proteinases (e.g. LysC or trypsin) results in a characteristic peptide map.
  • sequence-specific endo-proteinases e.g. LysC or trypsin
  • the resulting peptides can be separated by reversed phase chromatography and analyzed by mass spectrometry and/or N-terminal sequencing. This allows for a determination of the PEG-modified groups within the NK4 molecule.
  • MonoPEGylated NK4 can also be characterized by reversed phase chromatography. PEGylation of NK4 results in a change in retention time as compared to unmodified NK4.
  • NK4 monoPEGylated with PEG 5 kDa, PEG 20 kDa, PEG 30 kDa, PEG 40 kDa and multiPEGylated NK4 were used.
  • MDCK cells were subconfluently grown in tissue culture plates. Cells were treated with HGF (10 ng/ml) or with combinations of HGF and NK4. In these experiments the HGF-induced cell scattering was inhibited by the addition of a 10 to 1000-fold molar excess of NK4, showing the functional activity of PEGylated NK4. It was found that the in vitro activity of monoPEGylated 5 kDa-PEG-NK4, 20 kDa-PEG-NK4, 30 kDa-PEG-NK4, and 40 kDa-PEG-NK4 is similar to unPEGylated NK4.
  • NK4 Inhibition of the mitogenic activity of HGF by NK4 was determined by measuring proliferation of HUVECs in culture as described in Nakamura, T., et al., Nature 342 (1989) 440-443. In these experiments the HGF-induced cell proliferation was inhibited by the addition of a 10 to 1000-fold molar excess of NK4, showing the functional activity of monoPEGylated NK4 (FIGS. 1 and 2).
  • the HUVEC Proliferation assay was performed by inhibition of the mitogenic activity of bFGF (basic fibroblastic growth factor) by NK4. Inhibition was determined by measuring proliferation of HUVECs in culture as described in Kuba, K., et al., Cancer Res. 60 (2000) 6737-6743. In these experiments the FGF-induced cell proliferation was inhibited by the addition of a 10 to 1000-fold molar excess of NK4, showing the functional activity of monoPEGylated NK4 (FIG. 3).
  • Model Panc Tul human pancreatic cancer orthotopic SCID mouse model (Alves, F., et al., Pancreas 23 (2001) 227-235).
  • Treatment After 8 days, one application daily of monoPEGylated NK4 over a period of 21 days.
  • Treatment with monoPEGylated NK4 shows a dose-dependent suppression of primary tumor growth compared to placebo treated groups. For example, with a dose of 4 mg/kg/day of monoPEGylated NK4, a tumor volume of only 200 mm 3 was found compared to a tumor volume of 280 mm 3 in the placebo treated animal group.
  • Suitable pharmaceutical compositions are, for example:
  • compositions are prepared in that monoPEGylated NK4 is dialyzed against the above mentioned buffer solution (with or without mannitol).
  • the protein concentration is adjusted by concentration or dilution with the buffer solution.
  • Detergent and NaCl are added out of a 10% stock solution.
  • mice received single i.v. or s.c. bolus injections of NK4, 30 kDa-mono-PEG-NK4 or 40 kDa-mono-PEG-NK4 (4 mg/kg in 0.25 ml injection volume), respectively.
  • blood samples were taken and analyzed for NK4, 30 kDa-mono-PEG-NK4 or 40 kDa-mono-PEG-NK4 content by ELISA.
  • the time-concentration curves were calculated and are shown in FIGS. 4A and 4B. These data show that 30 kDa-mono-PEG-NK4 and 40 kDa-mono-PEG-NK4 have significantly improved stability in vivo, resulting in significantly increased plasma half-lives compared to unmodified NK4.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US10/081,309 2001-02-23 2002-02-21 PEG conjugates of NK4 Abandoned US20030012775A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/869,797 US7846896B2 (en) 2001-02-23 2007-10-10 PEG conjugates of NK4

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01104640A EP1234583A1 (en) 2001-02-23 2001-02-23 PEG-conjugates of HGF-NK4
EP01104640.6 2001-02-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/869,797 Division US7846896B2 (en) 2001-02-23 2007-10-10 PEG conjugates of NK4

Publications (1)

Publication Number Publication Date
US20030012775A1 true US20030012775A1 (en) 2003-01-16

Family

ID=8176596

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/081,309 Abandoned US20030012775A1 (en) 2001-02-23 2002-02-21 PEG conjugates of NK4
US11/869,797 Expired - Lifetime US7846896B2 (en) 2001-02-23 2007-10-10 PEG conjugates of NK4

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/869,797 Expired - Lifetime US7846896B2 (en) 2001-02-23 2007-10-10 PEG conjugates of NK4

Country Status (27)

Country Link
US (2) US20030012775A1 (es)
EP (2) EP1234583A1 (es)
JP (2) JP2004521139A (es)
KR (2) KR20030072629A (es)
CN (1) CN100339393C (es)
AR (1) AR032574A1 (es)
AU (1) AU2002233354B2 (es)
BG (1) BG108125A (es)
BR (1) BR0207510A (es)
CA (1) CA2438308A1 (es)
CZ (1) CZ20032511A3 (es)
EC (1) ECSP034741A (es)
GT (1) GT200200038A (es)
HR (1) HRP20030659A2 (es)
HU (1) HUP0400979A2 (es)
IL (1) IL157426A0 (es)
MA (1) MA26998A1 (es)
MX (1) MXPA03007130A (es)
NO (1) NO20033737L (es)
PA (1) PA8540501A1 (es)
PE (1) PE20020992A1 (es)
PL (1) PL367402A1 (es)
RU (1) RU2293574C2 (es)
SK (1) SK11652003A3 (es)
WO (1) WO2002074344A2 (es)
YU (1) YU65103A (es)
ZA (1) ZA200306080B (es)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
US9943568B2 (en) 2013-04-18 2018-04-17 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating cancer
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
US10143726B2 (en) 2014-10-22 2018-12-04 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10195274B2 (en) 2015-05-28 2019-02-05 Armo Biosciences Inc. Method of modulating a chimeric antigen receptor t cell immune response by administering IL-10
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
US10350270B2 (en) 2014-10-14 2019-07-16 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
US10532020B2 (en) 2012-08-22 2020-01-14 Revlon Consumer Products Corporation Nail coatings having enhanced adhesion
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019991A2 (en) * 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
WO2004085471A2 (en) * 2003-03-24 2004-10-07 Novo Nordisk A/S Glp-2 derivatives
ES2297673T3 (es) * 2004-03-03 2008-05-01 F. Hoffmann-La Roche Ag Metodo para la purificacion de un fragmento n-terminal del factor de crecimiento de hepatocitos.
JP2007525981A (ja) * 2004-03-03 2007-09-13 エフ．ホフマン−ラ　ロシュ　アーゲー 肝細胞成長因子のｎ末端フラグメントを組み換え発現するための方法
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
CA2720611C (en) * 2008-04-09 2016-07-12 Viromed Co., Ltd. Lyophilized dna formulations for enhanced expression of plasmid dna
CN102399293B (zh) * 2008-06-03 2013-12-04 中国科学院遗传与发育生物学研究所 一种与纤维蛋白特异结合的重组蛋白及其应用
BR112021012880A2 (pt) * 2019-01-28 2021-11-16 Toray Industries Forma modificada por polietileno glicol de um fator de crescimento de hepatócito ou um fragmento ativo do mesmo, e, medicamento
BR112021012472A2 (pt) * 2019-01-28 2021-11-30 Toray Industries Forma modificada por polietileno glicol de um fator de crescimento de hepatócito ou um fragmento ativo do mesmo, e, medicamento

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766581A (en) * 1994-03-31 1998-06-16 Amgen Inc. Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation
US5977310A (en) * 1995-03-10 1999-11-02 Toshikazu Nakamura And Sumitomo Pharmaceuticals Co., Ltd. Peg-modified HGF
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6340742B1 (en) * 1999-07-02 2002-01-22 Roche Diagnostics Gmbh Erythropoietin conjugates
US20020115833A1 (en) * 2000-12-20 2002-08-22 Josef Burg Erythropoietin conjugates
US6528485B1 (en) * 1997-12-03 2003-03-04 Applied Research Systems Ars Holding N.V. Site-specific preparation of polyethylene glycol-grf conjugates
US6583272B1 (en) * 1999-07-02 2003-06-24 Hoffmann-La Roche Inc. Erythropoietin conjugates
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2181689T3 (es) 1992-05-18 2003-03-01 Genentech Inc Variantes del factor de crecimiento de hepatocitos.
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
ES2093593T1 (es) * 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
WO1998031383A1 (en) 1997-01-15 1998-07-23 Phoenix Pharmacologics, Inc. Modified tumor necrosis factor
EA003789B1 (ru) * 1998-04-28 2003-10-30 Апплайд Резеч Системз Арс Холдинг Н.В. КОНЪЮГАТЫ ПОЛИОЛ-β-ИНТЕРФЕРОН
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766581A (en) * 1994-03-31 1998-06-16 Amgen Inc. Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation
US5977310A (en) * 1995-03-10 1999-11-02 Toshikazu Nakamura And Sumitomo Pharmaceuticals Co., Ltd. Peg-modified HGF
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6528485B1 (en) * 1997-12-03 2003-03-04 Applied Research Systems Ars Holding N.V. Site-specific preparation of polyethylene glycol-grf conjugates
US6340742B1 (en) * 1999-07-02 2002-01-22 Roche Diagnostics Gmbh Erythropoietin conjugates
US6583272B1 (en) * 1999-07-02 2003-06-24 Hoffmann-La Roche Inc. Erythropoietin conjugates
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US20020115833A1 (en) * 2000-12-20 2002-08-22 Josef Burg Erythropoietin conjugates

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532020B2 (en) 2012-08-22 2020-01-14 Revlon Consumer Products Corporation Nail coatings having enhanced adhesion
US9943568B2 (en) 2013-04-18 2018-04-17 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating cancer
US10357545B2 (en) 2013-04-18 2019-07-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating solid tumors
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10209261B2 (en) 2013-06-17 2019-02-19 Armo Biosciences Inc. Method for assessing protein identity and stability
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
US10350270B2 (en) 2014-10-14 2019-07-16 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
US10143726B2 (en) 2014-10-22 2018-12-04 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10653751B2 (en) 2014-10-22 2020-05-19 Armo Biosciences Inc. Methods of treating cancer metastasis by using interleukin-10
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
US10195274B2 (en) 2015-05-28 2019-02-05 Armo Biosciences Inc. Method of modulating a chimeric antigen receptor t cell immune response by administering IL-10
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers

Also Published As

Publication number Publication date
MA26998A1 (fr) 2004-12-20
BR0207510A (pt) 2004-07-27
ECSP034741A (es) 2003-10-28
CA2438308A1 (en) 2002-09-26
IL157426A0 (en) 2004-03-28
RU2003127395A (ru) 2005-03-20
JP2004521139A (ja) 2004-07-15
CN100339393C (zh) 2007-09-26
US7846896B2 (en) 2010-12-07
PL367402A1 (en) 2005-02-21
EP1234583A1 (en) 2002-08-28
WO2002074344A3 (en) 2003-12-04
KR20030072629A (ko) 2003-09-15
US20080085857A1 (en) 2008-04-10
JP2010174034A (ja) 2010-08-12
GT200200038A (es) 2002-09-30
RU2293574C2 (ru) 2007-02-20
WO2002074344A2 (en) 2002-09-26
PA8540501A1 (es) 2002-09-30
NO20033737D0 (no) 2003-08-22
EP1389132A2 (en) 2004-02-18
HRP20030659A2 (en) 2004-08-31
PE20020992A1 (es) 2002-11-01
ZA200306080B (en) 2004-11-23
SK11652003A3 (sk) 2004-05-04
KR20090020713A (ko) 2009-02-26
AU2002233354B2 (en) 2006-11-30
NO20033737L (no) 2003-10-21
CN1571679A (zh) 2005-01-26
HUP0400979A2 (hu) 2004-08-30
MXPA03007130A (es) 2003-11-18
CZ20032511A3 (en) 2004-03-17
YU65103A (sh) 2006-03-03
AR032574A1 (es) 2003-11-12
BG108125A (bg) 2004-09-30

Similar Documents

Publication Publication Date Title
US7846896B2 (en) PEG conjugates of NK4
AU2002233354A1 (en) PEG-conjugates of HGT-NK4
JP4190184B2 (ja) ポリエチレングリコールを有するエリスロポエチン接合体
CN100528235C (zh) 红细胞生成素共轭物
CA2405716C (en) Chemically modified novel erythropoietin stimulating protein compositions and methods
JP3727009B2 (ja) エリスロポエチン誘導体
US7311902B2 (en) Conjugates comprising human IL-18 and substitution mutants thereof
US20040110679A1 (en) Treatment of disturbances of iron distribution
JP5961730B2 (ja) 修飾されたエリスロポエチン
US20040110685A1 (en) Scatter factor/hepatocyte growth factor antagonist NK4 for the treatment of glioma

Legal Events

Date Code Title Description
AS Assignment

Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:F.HOFFMANN-LA ROCHE AG;REEL/FRAME:012910/0411

Effective date: 20020131

Owner name: F. HOFFMANN-LA ROCHE AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRANDT, MICHAEL;PAPADIMITRIOU, APOLLON;REEL/FRAME:012910/0397

Effective date: 20020129

AS Assignment

Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY

Free format text: DOCUMENT PREVIOUSLY RECORDED AT REEL 012910 FRAME 0411 CONTAINED AN ERROR IN PROPERTY NUMBER 10081301. DOCUMENT RE-RECORDED TO CORRECT ERRORS ON STATED REEL. ASSIGNORS HEREBY CONFIRMS THE ASSIGNMENT OF THE ENTIRE INTEREST.;ASSIGNOR:F. HOFFMANN-LA ROCHE AG;REEL/FRAME:013192/0123

Effective date: 20020131

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION